CY1110395T1 - Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης - Google Patents

Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης

Info

Publication number
CY1110395T1
CY1110395T1 CY20081100983T CY081100983T CY1110395T1 CY 1110395 T1 CY1110395 T1 CY 1110395T1 CY 20081100983 T CY20081100983 T CY 20081100983T CY 081100983 T CY081100983 T CY 081100983T CY 1110395 T1 CY1110395 T1 CY 1110395T1
Authority
CY
Cyprus
Prior art keywords
hydropyridine
producers
therapeutic agents
additional salts
acid additional
Prior art date
Application number
CY20081100983T
Other languages
English (en)
Inventor
Fumitoshi Asai
Taketoshi Ogawa
Naotoshi Yamamura
Teruhiko Inoue
Kazuyoshi Nakamura
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26595526&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110395(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of CY1110395T1 publication Critical patent/CY1110395T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Τα άλατα προσθήκης οξέος των παραγώγων τετραϋδροθειενοπυριδίνης της παρούσας εφεύρεσης εμφανίζουν εξαιρετική στοματική απορρόφηση, μεταβολισμό στη δραστική ένωση, και ανασταλτική συμπεριφορά έναντι συσσωμάτωσης αιμοπεταλίων, χαμηλή τοξικότητα, και εξαιρετική σταθερότητα φύλαξης και χειρισμού, και είναι χρήσιμα ως φάρμακα, κατά προτίμηση ως προληπτικά ή θεραπευτικά μέσα (ιδίως ως θεραπευτικά μέσα) για παθήσεις προκαλούμενες από θρόμβο ή έμβολο, κατά περαιτέρω προτίμηση ως προληπτικά ή θεραπευτικά μέσα (ιδίως ως θεραπευτικά μέσα) για θρόμβωση ή εμβολή.
CY20081100983T 2000-07-06 2008-09-11 Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης CY1110395T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000205396 2000-07-06
JP2000266780 2000-09-04
EP06017487A EP1728794B1 (en) 2000-07-06 2001-07-03 Maleate addition salt of hydropyridine derivatives

Publications (1)

Publication Number Publication Date
CY1110395T1 true CY1110395T1 (el) 2015-04-29

Family

ID=26595526

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20071100188T CY1107554T1 (el) 2000-07-06 2007-02-12 Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
CY20081100983T CY1110395T1 (el) 2000-07-06 2008-09-11 Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
CY2009011C CY2009011I1 (el) 2000-07-06 2009-08-03 Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100188T CY1107554T1 (el) 2000-07-06 2007-02-12 Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2009011C CY2009011I1 (el) 2000-07-06 2009-08-03 Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης

Country Status (24)

Country Link
US (1) US6693115B2 (el)
EP (2) EP1298132B1 (el)
KR (6) KR20100105763A (el)
CN (1) CN1214031C (el)
AT (2) ATE398624T1 (el)
AU (2) AU6791601A (el)
BR (1) BR0112168A (el)
CA (2) CA2703697C (el)
CY (3) CY1107554T1 (el)
CZ (1) CZ302990B6 (el)
DE (2) DE60134508D1 (el)
DK (2) DK1728794T3 (el)
ES (2) ES2308633T3 (el)
HK (2) HK1051362A1 (el)
HU (2) HU227746B1 (el)
IL (2) IL153546A0 (el)
MX (1) MXPA03000031A (el)
NO (1) NO328651B1 (el)
NZ (1) NZ523416A (el)
PL (1) PL208386B1 (el)
PT (2) PT1298132E (el)
RU (1) RU2238275C1 (el)
TW (1) TWI290927B (el)
WO (1) WO2002004461A1 (el)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2262933C2 (ru) 2000-12-25 2005-10-27 Санкио Компани, Лимитед Медицинские композиции, содержащие аспирин
CA2493384A1 (en) * 2002-07-18 2004-01-29 Sankyo Company Limited Medicinal composition for treating arteriosclerosis
WO2004098713A2 (en) * 2003-05-05 2004-11-18 Eli Lilly And Company Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
CN1318428C (zh) * 2005-02-23 2007-05-30 天津药物研究院 噻吩并吡啶取代的乙酰肼衍生物
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
CN101198329A (zh) * 2005-06-17 2008-06-11 伊莱利利公司 普拉格雷给药方案
US20080214599A1 (en) * 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
US8056072B2 (en) 2005-10-31 2011-11-08 Microsoft Corporation Rebootless display driver upgrades
PL2007362T3 (pl) 2006-04-04 2019-02-28 Kg Acquisition Llc Doustne postacie leku obejmujące czynnik przeciwpłytkowy i inhibitor kwasu
TWI392681B (zh) * 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法
CA2655061A1 (en) * 2006-06-27 2008-01-03 Sandoz Ag New method for salt preparation
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
BRPI0719398A2 (pt) * 2006-12-07 2015-03-31 Daiichi Sankyo Company Ltd E Ube Ind Ltd Composição farmacêutica.
US20110201814A1 (en) * 2006-12-07 2011-08-18 Daiichi Sankyo Company Limited Method for producing solid preparation
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
CN101594865A (zh) * 2006-12-07 2009-12-02 第一三共株式会社 含有低取代的羟基丙基纤维素的药物组合物
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY
CA2679925C (en) * 2007-03-02 2012-10-02 Daiichi Sankyo Company, Limited Method for producing high-purity prasugrel hydrochloride
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
CZ302135B6 (cs) * 2007-07-09 2010-11-10 Zentiva, A. S. Zpusob výroby 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4, 5, 6, 7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu)
EP2205611A4 (en) * 2007-11-09 2012-02-22 Reddys Lab Ltd Dr PROCESS FOR THE PRODUCTION OF PRASUGREL AND SALTS AND POLYMERS THEREOF
HU230261B1 (hu) * 2007-11-27 2015-11-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás gyógyszeripari intermedierek előállítására
CN101177430A (zh) * 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
WO2010015144A1 (zh) 2008-08-02 2010-02-11 鲁南制药集团股份有限公司 普拉格雷硫酸氢盐及其药物组合物和应用
US20110003847A1 (en) * 2008-02-06 2011-01-06 Helm Ag Prasugrel Salts with Improved Properties
WO2009129983A1 (en) * 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
ATE482961T1 (de) * 2008-04-25 2010-10-15 Sandoz Ag Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) * 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) * 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
JP5501438B2 (ja) 2009-03-31 2014-05-21 上海医薬工業研究院 プラスグレル臭化水素酸塩の結晶
WO2010118435A2 (en) 2009-04-10 2010-10-14 Tufts Medical Center, Inc. Par-1 activation by metalloproteinase-1 (mmp-1)
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
WO2011004392A1 (en) * 2009-07-06 2011-01-13 Glenmark Generics Limited Crystalline form of prasugrel hydrobromide, preparation and application thereof
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
CN101993447A (zh) 2009-08-26 2011-03-30 浙江华海药业股份有限公司 一种人工合成普拉格雷的方法
WO2011036533A1 (en) * 2009-09-23 2011-03-31 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising prasugrel and triflusal
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (en) 2009-11-11 2018-02-13 The Medicines Company Methods of treating or preventing stent thrombosis
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ2009763A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a jeho nových farmaceuticky prijatelných solí.
CZ2009828A3 (cs) 2009-12-09 2011-06-22 Zentiva, K.S. Zpusob prípravy hydrochloridu 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu (prasugrelu hydrochloridu) v polymorfní forme B
HU229035B1 (en) * 2009-12-21 2013-07-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing prasurgel
WO2011092720A2 (en) * 2010-02-01 2011-08-04 Msn Laboratories Limited Pharmaceutical composition of prasugrel and its pharmaceutically acceptable salts
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2545059A1 (en) 2010-03-09 2013-01-16 Synthon BV A process for making prasugrel
KR101184915B1 (ko) 2010-03-11 2012-09-21 한미사이언스 주식회사 고순도 프라수그렐의 제조방법
WO2011117782A1 (en) 2010-03-23 2011-09-29 Alembic Pharmaceuticals Limited A process for the preparation of prasugrel hcl salt
EP2377520A1 (de) 2010-03-24 2011-10-19 Ratiopharm GmbH Pharmazeutische Zusammensetzung des Prasugrels
CN102212068A (zh) * 2010-04-06 2011-10-12 刘桂坤 噻吩衍生物及其制备方法和在药物上的应用
CN102212071B (zh) * 2010-04-08 2014-03-26 上海医药工业研究院 普拉格雷盐酸盐乙酸溶剂合物及其结晶和制备方法
KR20140110096A (ko) 2010-04-08 2014-09-16 테바 파마슈티컬 인더스트리즈 리미티드 프라수그렐 염의 결정형
ES2592280T3 (es) 2010-04-19 2016-11-29 Cadila Healthcare Limited Una composición farmacéutica que comprende agentes antiplaquetarios y un agente estimulante de eritropoyesis
WO2012001486A1 (en) * 2010-06-28 2012-01-05 Mayuka Labs Pvt. Ltd. An improved process for the preparation of prasugrel hydrochloride and its intermediates
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2012023145A2 (en) * 2010-08-18 2012-02-23 Hetero Research Foundation Prasugrel hydrochloride crystalline particles
HUP1000565A2 (en) 2010-10-22 2012-05-02 Egis Gyogyszergyar Nyrt Process for the preparation of pharmaceutically active compound and intermediers
CN101985450B (zh) * 2010-11-02 2012-07-11 北京赛科药业有限责任公司 普拉格雷盐及其制备方法
CN102532157A (zh) * 2010-12-16 2012-07-04 瑞阳制药有限公司 普拉格雷的可药用酸加成盐化合物及其制备方法
CZ305314B6 (cs) * 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby
CN102199163A (zh) * 2011-04-01 2011-09-28 中国药科大学 2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途
CN102746318A (zh) * 2011-04-20 2012-10-24 上海信谊药厂有限公司 用于制备普拉格雷盐酸盐的方法
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
JP2014515352A (ja) 2011-05-17 2014-06-30 ベリコ メディカル インコーポレイティッド シアリダーゼ阻害剤を用いた血小板の保存の改善法
CN102838618A (zh) * 2011-06-22 2012-12-26 广东东阳光药业有限公司 一种制备普拉格雷的方法及普拉格雷盐酸盐新晶型
WO2013014295A1 (en) 2011-07-28 2013-01-31 Laboratorios Lesvi, S. L. Process for preparing prasugrel
CN103102355A (zh) * 2011-11-09 2013-05-15 丁克 具有旋光性的四氢噻吩并吡啶化合物
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
EP2903430A1 (en) 2012-10-05 2015-08-12 Velico Medical, Inc. Platelet additive solution having a beta-galactosidase inhibitor
EP2722036A1 (en) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral formulations of prasugrel
WO2014060554A1 (en) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Prasugrel formulations
PL402028A1 (pl) 2012-12-12 2014-06-23 Instytut Farmaceutyczny Sposób wytwarzania postaci polimorficznej B chlorowodorku prasugrelu o czystości farmaceutycznej
HU230649B1 (hu) 2013-01-24 2017-05-29 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Javított eljárás prasugrel gyógyszeripari hatóanyag és az 1-ciklopropil-2-(2-fluorofenil)-etanon intermedier előállítására
WO2014120886A1 (en) 2013-01-30 2014-08-07 Velico Medical, Inc. Platelet additive solution having a self-assembling hydrogel-forming peptide
KR102235732B1 (ko) 2013-12-26 2021-04-02 에스케이플래닛 주식회사 쿠폰 관리 시스템 및 방법, 그리고 이를 위한 장치 및 컴퓨터 프로그램이 기록된 기록매체
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
EP2979693A1 (en) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
CN104479502A (zh) * 2014-12-31 2015-04-01 江阴市天邦涂料股份有限公司 一种水性防腐涂料
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
EP3156049A1 (en) 2015-10-15 2017-04-19 Alembic Pharmaceuticals Limited Pharmaceutical composition of prasugrel
EP3158993A1 (en) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
EP3528790A1 (en) 2016-10-21 2019-08-28 Laboratorios Lesvi S.L. Pharmaceutical formulations of prasugrel and processes for the preparation thereof
CN106632391A (zh) * 2016-12-23 2017-05-10 山东鲁抗医药股份有限公司 一种盐酸普拉格雷化合物及其制备方法和含有盐酸普拉格雷的药物组合物
MX2019015448A (es) 2017-06-23 2020-02-19 Chiesi Farm Spa Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
KR102063862B1 (ko) 2018-08-09 2020-01-08 한국기술교육대학교 산학협력단 Qr코드 기반의 공유시점관리 시스템
KR102485021B1 (ko) 2020-11-18 2023-01-05 효성중공업 주식회사 델타구조 반도체변압기 기반 에너지 저장장치의 SoC 균등제어 장치 및 방법
KR102491932B1 (ko) 2020-11-18 2023-01-27 현대엠시스템즈 주식회사 통신 방식 가변형 원격 모니터링 제어 시스템 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141894A (en) * 1976-11-02 1979-02-27 Eli Lilly And Company Trans-5a-aryl-decahydrobenzazepines
FR2576901B1 (fr) 1985-01-31 1987-03-20 Sanofi Sa Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
JP2506376B2 (ja) * 1987-07-16 1996-06-12 三菱化学株式会社 ２−（４−メチルアミノブトキシ）ジフェニルメタン・塩酸塩の製造方法
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
JPH07188168A (ja) * 1993-12-28 1995-07-25 Fujisawa Pharmaceut Co Ltd ジヒドロピリジン化合物およびその製造方法
RU2262933C2 (ru) * 2000-12-25 2005-10-27 Санкио Компани, Лимитед Медицинские композиции, содержащие аспирин
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CZ305314B6 (cs) 2010-12-30 2015-07-29 Zentiva, K.S. Nový hydrobromid formy C 5-[2-cyklopropyl-1-(2-fluorofenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráněným názvem prasugrel a způsob jeho výroby

Also Published As

Publication number Publication date
US20030134872A1 (en) 2003-07-17
PL208386B1 (pl) 2011-04-29
HK1096684A1 (en) 2007-07-20
MXPA03000031A (es) 2003-10-15
DK1728794T3 (da) 2008-09-22
CN1452624A (zh) 2003-10-29
KR20120062906A (ko) 2012-06-14
CA2415558A1 (en) 2002-01-17
DE60124712D1 (de) 2007-01-04
US6693115B2 (en) 2004-02-17
NO20030022D0 (no) 2003-01-03
AU6791601A (en) 2002-01-21
CA2703697A1 (en) 2002-01-17
NZ523416A (en) 2004-10-29
PL359393A1 (en) 2004-08-23
HK1051362A1 (en) 2003-08-01
EP1728794A1 (en) 2006-12-06
CA2415558C (en) 2010-09-14
WO2002004461A1 (fr) 2002-01-17
AU2001267916B2 (en) 2004-09-09
KR20130118395A (ko) 2013-10-29
CN1214031C (zh) 2005-08-10
CZ200318A3 (cs) 2003-05-14
CY2009011I2 (el) 2010-07-28
KR20100105763A (ko) 2010-09-29
EP1298132A4 (en) 2004-03-10
HU227746B1 (en) 2012-02-28
IL153546A (en) 2007-03-08
ATE398624T1 (de) 2008-07-15
CY2009011I1 (el) 2010-07-28
NO328651B1 (no) 2010-04-19
CY1107554T1 (el) 2010-07-28
KR20080021152A (ko) 2008-03-06
KR20030014294A (ko) 2003-02-15
BR0112168A (pt) 2003-09-02
PT1298132E (pt) 2007-01-31
NO20030022L (no) 2003-03-05
DK1298132T3 (da) 2007-03-12
HUP0301645A3 (en) 2006-05-29
CZ302990B6 (cs) 2012-02-08
PT1728794E (pt) 2008-07-15
EP1298132A1 (en) 2003-04-02
HUP1100350A2 (en) 2003-09-29
ES2308633T3 (es) 2008-12-01
KR20090033917A (ko) 2009-04-06
EP1728794B1 (en) 2008-06-18
ES2276801T3 (es) 2007-07-01
HU230762B1 (hu) 2018-03-28
ATE346071T1 (de) 2006-12-15
CA2703697C (en) 2012-09-04
RU2238275C1 (ru) 2004-10-20
EP1298132B1 (en) 2006-11-22
DE60124712T2 (de) 2007-09-13
HUP0301645A2 (hu) 2003-09-29
TWI290927B (en) 2007-12-11
DE60134508D1 (de) 2008-07-31
IL153546A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
CY1110395T1 (el) Αλατα προσθηκης οξεος παραγωγων υδροπυριδινης
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
CY1108626T1 (el) Ιαματικες συνθεσεις που περιεχουν ασπιρινη
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
CY1112084T1 (el) Παραγωγα 5-φαινυλθειαζολης και χρηση ως αναστολεις της κινασης ρi3
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
ATE504579T1 (de) Antivirale mittel
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
DE69223914D1 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
ATE316083T1 (de) Adamantanderivate
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
SE0101932D0 (sv) Pharmaceutical combinations
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
NO20021337D0 (no) 4-benzylaminoquinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlersom inneholder disse forbindelser og deres anvendelse
DE60039782D1 (de) Amidinophenylbrenztraubensäure-derivat
SE0301698D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof